01488nam a2200289 4500 ESSALUD 20260902163508.0 ta t pe ||||| |||| 00| 0 spa d BMG eng Lundberg, Ingrid E. 54489 A Phase 3 Trial of brepocitinib in dermatomyositis páginas: 1953-1955 Dermatomyositis is a subgroup of idiopathic inflammatory myopathies — systemic autoimmune disorders that are typically characterized by the involvement of multiple organs, including muscle, skin, joints, lungs, gastrointestinal tract, and heart — all conditions with high morbidity and mortality. Treatment of myositis is based on off-label use of high doses of glucocorticoids, usually over long periods of time, in combination with immune-modulating agents and physical exercise. However, the outcome is often disappointing, with persisting inflammation and recurrent flares. ALERGIA 7055 INMUNOLOGÍA GENERAL 53664 ENFERMEDAD AUTOINMUNE 53665 DERMATOLOGÍA GENERAL 54449 ENFERMEDAD PULMONAR INTERSTICIAL 53691 ENFERMEDAD NEUROMUSCULAR 53763 NEUROLOGÍA NEUROCIRUGÍA 7782 CÉLULAS T 54097 22717 22669 Massachusetts NEJM Group NEJM014 The New England Journal of Medicine ESSALUD 0028-4793 ARTICULOS 2026-08-31 sqb 22907 22907